Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Infection during biologic and immunosuppressive treatment

Infectious diseases, microbiology and sexual health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Serious infection with blunted inflammation

Shock, hypoxaemia, meningism, encephalopathy, severe abdominal pain, disseminated vesicles or rapidly progressive focal disease can occur with little fever, leukocytosis or CRP response during targeted immune suppression.

Action: Use ABCDE, obtain cultures and focused samples without harmful delay, start syndrome-appropriate empirical treatment and involve microbiology or infection specialists. Withhold the implicated biologic or targeted drug in serious infection after urgent specialist communication, but never abruptly stop chronic corticosteroids.

Synopsis

Infer infection risk from the targeted immune defect, recognise masked and opportunistic presentations, treat serious infection promptly and coordinate safe interruption, prophylaxis and restart of immunosuppression.

  • Name every immune-modifying medicine, last dose, cumulative corticosteroid exposure and combination therapy; risk follows mechanism and intensity rather than the word biologic alone.
  • TNF inhibition impairs granuloma maintenance and raises tuberculosis and other intracellular-pathogen risk; monoclonal anti-TNF antibodies generally carry greater TB-reactivation concern than etanercept.
  • B-cell depletion can cause hepatitis B reactivation, hypogammaglobulinaemia, impaired vaccine responses and prolonged viral susceptibility months after the last infusion.
  • JAK inhibitors increase serious infection and herpes zoster risk; MHRA restrictions also address cardiovascular, malignant and thrombotic harms when choosing treatment.
  • IL-6 blockade can suppress fever and CRP, so examination, physiology, imaging and microbiology must outweigh reassuring inflammatory markers.
  • Terminal-complement blockade creates exceptional meningococcal susceptibility that vaccination reduces but cannot abolish; suspected disease receives immediate emergency antibiotics.
  • Serious infection usually requires temporary interruption of a biologic or targeted immunosuppressant, while corticosteroid continuation and stress dosing prevent adrenal crisis.
  • Empirical antimicrobials follow the anatomical syndrome and local resistance data; the drug mechanism refines pathogen coverage and sampling rather than dictating one universal regimen.

Key red flags

Hypotension, confusion, new oxygen need, oliguria or rising lactate is serious infection regardless of a normal temperature or inflammatory marker.

Persistent cough, weight loss, night sweats, lymphadenopathy or a compatible exposure during anti-TNF therapy requires urgent active-tuberculosis assessment and respiratory isolation when pulmonary disease is possible.

Severe abdominal pain or peritonism during IL-6 blockade may represent bowel perforation or sepsis despite a muted CRP response.

Headache, photophobia, purpura or rapidly evolving sepsis during terminal-complement inhibition is meningococcal disease until treated, even after vaccination.

Widespread vesicles, ophthalmic involvement, neurological symptoms or visceral features during JAK inhibition or corticosteroid therapy suggests disseminated VZV.

Jaundice or major ALT rise during rituximab, intensive chemotherapy or prolonged immunosuppression may indicate hepatitis B reactivation and requires urgent HBV DNA testing and hepatology input.

Masked bacterial sepsis

Fatigue, confusion, tachypnoea, hypotension or focal pain can precede fever and CRP elevation during corticosteroid or IL-6-pathway suppression.

Herpesvirus disease

Dermatomal pain, grouped vesicles, disseminated rash, ocular symptoms or neurological change during JAK inhibition or combined therapy requires rapid HSV or VZV assessment.

Investigation priorities

01
Treatment and immune-defect inventoryFirst step

Identify the mechanistic infection pattern, duration of residual effect and medicines that require temporary interruption or interaction review.

02
First-line syndrome samplingFirst line

Diagnose common bacterial, viral or fungal infection and secure susceptibility data before empirical treatment reduces yield.

Management branches

ACUTE ILLNESSTreat the clinical syndrome

A patient receiving an immune-modifying medicine develops possible serious infection or sepsis physiology.

  1. Perform ABCDE, obtain blood and focus cultures immediately and start the local syndrome-specific empirical regimen when severe infection is possible.
  2. Identify the immune mechanism and add tests or cover only for credible gaps, such as tuberculosis with anti-TNF, VZV with JAK inhibition or meningococcus with complement blockade.
  3. Withhold the biologic or targeted agent during serious infection and contact its prescribing team; continue necessary corticosteroid and provide stress cover when indicated.
  4. Control the anatomical source and narrow antimicrobials from culture, molecular or tissue results rather than continuing broad opportunistic coverage indefinitely.

Key medicines

Syndrome-directed empirical antimicrobialsUse the current local severe-infection regimen for the anatomical source at full loading dose, modified immediately for immune mechanism, allergy, organ function, prior organisms and resistance exposure.Avoid an unfocused antibacterial, antiviral and antifungal bundle; obtain decisive samples, check interactions with immunosuppressants and set a 24- to 48-hour narrowing point.
Co-trimoxazole prophylaxisA commonly used adult regimen is 960 mg orally three times weekly or 480 mg once daily when specialist assessment identifies material Pneumocystis risk.Check allergy, FBC, creatinine and potassium and interactions with methotrexate, renin-angiotensin drugs and marrow-suppressive therapy; pregnancy and glucose-6-phosphate dehydrogenase status may alter the plan.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis
  • 2025 British Society for Rheumatology guideline for prescription and monitoring of conventional synthetic DMARDs
  • Janus kinase inhibitors: new measures to reduce serious infections and other major risks
  • RoActemra 20 mg/ml Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc) | 9086
  • MabThera 500 mg Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc) | 3801

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Complement-associated sepsis

Abrupt fever, severe myalgia, headache, vomiting, purpura or shock with eculizumab or ravulizumab exposure warrants immediate meningococcal treatment despite previous vaccination.